AR

Aditya Rajagopal

Chairperson at Wisdom Biosciences

Mountain View, California

Overview 

Aditya Rajagopal is the CEO of Esperto Medical, a role in which he oversees the company's operations and strategic direction. With a background in Bioinformatics and Biomedical Engineering, he has founded and chaired successful companies like ChromaCode, Inc., and served as an advisor and board member for various organizations in the healthcare and biotech sectors. Rajagopal holds a Doctor of Philosophy (PhD) and Master of Science (MS) from Caltech, and has made significant contributions to the field of medical technology through his leadership roles, including serving as an Adjunct Assistant Professor at the University of Southern California and a Visiting Scholar at Stanford University's Canary Institute for Early Cancer Detection.

Work Experience 

  • CEO, Chairman, Co-Founder

    2018 - Current

    Caltech spin-out utilizing compressed sensing methods with ultrasound to continuously and non-invasively measure blood pressure. Backed by Maverick Ventures and others.

Esperto's patented technology uses sound waves to measure blood pressure without an inflating cuff

  • Founder & Chairman

    2012

    We are a multiplexed molecular diagnostics company with a bioinformatics focus and pedigree from Google[x], Illumina, Luminex, and Caltech. We are transforming the multi-billion dollar molecular diagnostics industry by democratizing personalized medicine. I am the Founder and Member of the Board of Directors of ChromaCode, and the inventor of core technologies related to combinatorics for biochemical labeling, multiplexed PCR assay design, and algorithms for data processing. Served as CTO from 2012 - 2024.

ChromaCode is a molecular diagnostics company focusing on bioinformatics.

Raised $93,967,513.00 from Global Brain Corporation.

  • Chairperson

    2024

    Enabling dental offices with better patient diagnostics.

  • Independent Board Director

    2020

    Camena Bioscience utilizes novel "geometric synthesis" methods to build oligo nucleotides for synthetic biology with significantly higher length and purity. Advisor to Board of Directors and CEO (2020 - 2023) Independent Board Director (2023 - present)

  • Advisor

    2022

Erisyon is commercializing the world’s first single molecule protein sequencer

Raised $225,000.00 from Musea Ventures.

  • Visiting Associate (Visiting Faculty)

    2016

    I lead, fund, and manage a research group working on interesting things at the nexus of biology, medicine, and engineering. HDPCR (commercialized by ChromaCode) is the first technology to be transitioned into industry from our lab. Compressed sensing with ultrasound (commercialized by Esperto Medical) is the second.

  • Adjunct Assistant Professor, Biomedical Engineering

    2018

    I work on interesting problems related to fluorescence imaging methods.

  • Advisor

    2018 - 2024

    LunaPBC is the first community-owned health and DNA data platform dedicated to advancing research through community engagement, and personal data ownership, control and transparency. Founded by former executive leadership from Illumina and funded by Illumina Ventures and Arch Ventures. Serve as an advisor to the founders of the company.

LunaPBC is a healthcare company that transforms health data into health breakthroughs.

Raised $11,443,707.00 from ARCH Venture Partners, Illumina Ventures, Bain Capital Ventures, F-Prime Capital and OUP (Osage University Partners).

  • Venture Partner

    2020 - 2022

    Investing at the nexus of data science, physical science, and life science. ND Capital investments include: Public: TWST, ARMO, SQZ Private: Visby, Inscripta

NanoDimension is a venture capital firm investing in disruptive technologies in and at the convergence of the life and physical sciences.

  • Visting Scholar, Canary Institute for Early Cancer Detection

    2018 - 2020

Articles About Aditya

Relevant Websites